• Recruiting

NCT05024045: Phase 1 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

Updated: Jun 13

NCT05024045: Phase 1 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers


LOXO 338

The purpose of this study is to find out whether the study drug, LOXO-338, is safe and effective in patients with advanced blood cancer. Patients must have already received standard therapy. The study may last up to approximately 3 years.


Leukemia, Lymphocytic, Chronic, B-Cell

Lymphoma, B-cell Marginal Zone

Lymphoma, Non-Hodgkin

Multiple Myeloma

B-cell Lymphoma

Waldenstrom Macroglobulinemia

Lymphoma, Mantle-Cell


Sponsor

Eli Lilly and Company


Collaborator

Loxo Oncology, Inc


Multiple Locations

International Study

 

ClinicalTrials.gov Identifier: NCT05024045


Official Title: A Phase 1 Study of Oral LOXO-338, a Selective BCL-2 Inhibitor, in Patients With Advanced Hematologic Malignancies


First Posted : August 27, 2021


Click here for details on ClinicalTrials.gov

 

Drug: LOXO-338

Bcl-2 inhibitor LOXO-338

Drug: Pirtobrutinib

BTK inhibitor LOXO-305

 

Drug: LOXO-338

Bcl-2 inhibitor LOXO-338

Drug: Pirtobrutinib

BTK inhibitor LOXO-305

 

Locations

United States, Florida

United States, Indiana

United States, Kansas

United States, Minnesota

United States, New York

United States, Washington

United States, Wisconsin

Europe

France

Poland

 

Posts Archive